Dashboard/BETA

BETA

FAIRLY_VALUED

Beta Drugs Limited

Pharma · NSE

↓ 17.9% vs fair value

52W Low

₹990

+36.4% from low

52W High

₹2,000

-32.5% from high

News sentiment
9 bull6 neu1 bear

Valuation Gauge

FAIRLY_VALUED-17.9% Margin of Safety
OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹1,351

Fair Value

₹1,145

Fair Value Analysis

₹1,145

Based on earnings growth potential for Pharma sector companies | CAUTION: ROCE declining (latest 22.4%) — returns on capital are falling; verify this isn't a value trap.

Low confidence

Growth Valuation

100% weight

₹1,145

Price vs Market

BETA
Nifty 50

Shareholding Pattern

Stock Health Score

B

Solid Fundamentals

6.2 / 10

Profitability

8/10

ROE of 13.4% is acceptable for Pharma sector (benchmark: 18%)

Debt & Leverage

10/10

D/E ratio of 0.7x is well within the Pharma sector norm of 0.8x — strong balance sheet

Valuation vs Peers

6/10

P/E of 42.9x is in line with the Pharma sector median of 42x — fairly valued

Cash Flow

1/10

Negative FCF of ₹-1 Cr — company is consuming more cash than it generates

Earnings Growth

8/10

5yr EPS CAGR of 19.6% is in line with the Pharma sector average of 15.3%

Dividend

4/10

No dividend — typical for growth-stage companies

Company Health Timeline

10-year financial health at a glance

FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue Growthⓘ
OPM %ⓘ
Net Profitⓘ
Free Cash Flowⓘ
ROE %ⓘ
ROCE %ⓘ
Debt / Equityⓘ
Interest Cov.ⓘ
Health Score
100
88
88
100
100
100
100
88
Strong
Moderate
Weak
Poor
No data

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

Operating Cash Flow

₹36 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹29.4

P/E Ratio

42.9x

P/B Ratio

5.8x

ROE

13.4%

ROCE

19.1%

Debt / Equity

0.66x

Beta

-0.45

Div Yield

—

FCF (Cr)

₹-1 Cr

Revenue (Cr)

₹362 Cr

EPS Growth 5Y

19.6%

Mkt Cap (Cr)

₹1,284 Cr

52W High

₹2,000

52W Low

₹990.1

Book Value/Share

₹217.9

Financial History

PeriodRevenueOp ProfitOPM%PATEPS
2025-03-31₹362 Cr₹75 Cr21.0%₹42 Cr₹42.02
2024-03-31₹296 Cr₹60 Cr20.0%₹36 Cr₹36.08
2023-03-31₹227 Cr₹53 Cr23.0%₹31 Cr₹30.42
2022-03-31₹184 Cr₹43 Cr23.0%₹25 Cr₹24.58
2021-03-31₹116 Cr₹25 Cr21.0%₹12 Cr₹11.60
2020-03-31₹91 Cr₹18 Cr20.0%₹9 Cr₹9.33
2019-03-31₹66 Cr₹12 Cr18.0%₹8 Cr₹8.84
2018-03-31₹51 Cr₹9 Cr19.0%₹7 Cr₹7.43

Compounded Growth Rates

Sales Growth

3Y+25.3%
5Y+31.8%
10Y—

Profit Growth

3Y+18.9%
5Y+36.1%
10Y—

EPS Growth

3Y+19.6%
5Y+35.1%
10Y—

Peer Comparison

Pharma
StockPriceFair ValueMoS%P/EROESignal
PAR

Par Drugs And Chemicals Limited

₹86.4₹469.7+81.6%7.715.4%FAIRLY_VALUED
IOLCP

IOL Chemicals and Pharmaceuticals Limited

₹118.2₹237.8+50.3%26.85.2%FAIRLY_VALUED
BALPHARMA

Bal Pharma Limited

₹82.3₹147.5+44.2%15.712.6%FAIRLY_VALUED
LINCOLN

Lincoln Pharmaceuticals Limited

₹732.1₹1,131.6+35.3%14.713.1%FAIRLY_VALUED
ZYDUSLIFE

Zydus Lifesciences

₹1,038.6₹1,502.2+30.9%20.619.9%UNDERVALUED
LUPIN

Lupin

₹2,270.7₹3,112+27.0%19.526.9%UNDERVALUED
NATCOPHARM

Natco Pharma

₹1,170₹1,571.3+25.5%13.818.0%UNDERVALUED
SUDEEPPHRM

Sudeep Pharma Limited

₹675₹739.2+8.7%43.721.4%FAIRLY_VALUED

Institutional Activity

Bulk deals, block deals, short selling & delivery volume — NSE data

Insider Trading

Community Pulse

Exchange Filings

BSE announcements · last 90 days

NSE ↗BSE ↗
Loading filings…

Share this Stock

Download card · Share on WhatsApp

BETA share card

Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant